RESUMO
BACKGROUND: Obesity has emerged as major public health problem leading to increased morbidity and mortality. Epidemiological studies indicate that in many regions of the world, children and teenagers are increasingly affected by obesity, which contributes for a pessimistic projection for the near future. Maternal obesity has been implicated in metabolic disorders of the offspring, but there are no biological markers that can be detected early on life that predict the development of obesity in the offspring. OBJECTIVE: To evaluate the expression of inflammatory markers in the umbilical cord blood of babies of mothers with obesity/overweight, and correlate these markers with the body weight at age 9 months. METHODS: Anthropometric data of mothers and babies were obtained during prenatal evaluation, at birth and 9 months after birth. Cord blood was collected during delivery of 54 babies from mothers with obesity/overweight and of 50 babies from lean mothers. Tumour necrosis factor-alpha (TNF-α), transforming growth factor 1 beta, monocyte chemoattractant protein-1 and 2 (MCP-1/MCP-2) were determined in serum samples using enzyme-linked immunosorbent assay methods. Correlations were evaluated using the Spearman correlation coefficient, and comparisons were evaluated using the non-parametric Mann-Whitney U-test. RESULTS: Cord blood TNF-α was positively correlated with maternal body mass index. There was an inverse correlation between cord blood transforming growth factor 1 beta and baby body weight at birth. There was no biological marker that predicted body weight at age 9 months. CONCLUSION: Although we have not found a biological marker to predict increased body weight at 9 months of age, the study shows that maternal obesity exposes the baby to higher TNF-α level in the early stages of life, and this can affect metabolic and inflammatory parameters during adulthood.
RESUMO
The present study examines the effect of concanavalin A (Con A) on the blood insulin and glucose levels of rats. Male and female rats treated with Con A (62.5-500 micrograms/kg) for three days showed a dose- and time-dependent hyperinsulinemia that lasted more than 48 h. Male rats were more sensitive to Con A. Thus, 6 h after treatment with Con A the circulating insulin levels in male rats had increased by 85% (control: 10.2 +/- 0.9 mU/l and Con A-treated: 18.8 +/- 1 mU/l) compared to only 38% (control: 7.5 +/- 0.2 mU/l; Con A-treated: 10.3 +/- mU/l) in females. An identical response was seen after 12 h. Con A (250 micrograms/kg) produced time-dependent hypoglycemia in both sexes but more pronounced in males. There was no correlation between the hypoglycemia and hyperinsulinemia described above. The Con A-induced hyperinsulinemia in rats of both sexes was abolished in gonadectomized animals (intact males: +101 +/- 17% vs orchiectomized males: -5 +/- 3%; intact females: +86 +/- 23% vs ovariectomized females: -18 +/- 7.2%). Pretreating intact male and female rats with human chorionic gonadotropin also significantly inhibited the Con A-induced hyperinsulinemia. Estradiol (10 micrograms/kg,i.m.) significantly blocked the Con A-induced increase in circulating insulin in male rats (101 +/- 17% for controls vs 32 +/- 5.3% for estradiol-treated animals, P < 0.05) while testosterone (10 mg/kg, i.m.) had no similar effect on intact female rats. Pretreating Con A-injected rats with opioid antagonists such as naloxone (1 mg/kg, s.c.) and naltrexone (5 mg/kg, s.c.) blocked the hyperinsulinemia produced by the lectin in males (control: +101 +/- 17% vs naloxone-treated: +5 +/- 14%, or naltrexone-treated: -23 +/- 4.5%) and females (control: +86 +/- 23% vs naloxone-treated: +21 +/- 20%, or naltrexone-treated: -18 +/- 11%). These results demonstrate that Con A increases the levels of circulating insulin in rats and that this response is opioid-dependent and hormonally regulated.
